SuperworthLifecore Biomedical profit margin LFCR
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- n/m
- a quarter missing
- Peer median
- 13.6%
Lifecore Biomedical's net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −30.0% | −13.4% | 31.3% |
| FY2024 | 9.4% | −6.9% | 32.6% |
| FY2023 | −96.4% | −21.1% | 27.1% |
| FY2022 | n/a | −35.3% | 35.1% |
| FY2021 | −19.0% | −6.0% | 29.4% |
| FY2020 | −6.5% | −6.5% | 12.7% |
| FY2019 | 0.1% | 1.0% | 14.5% |
| FY2018 | 4.7% | 2.6% | 14.9% |
| FY2017 | 2.3% | 3.3% | 16.9% |
| FY2016 | −2.2% | −3.7% | 13.1% |
| FY2015 | 2.5% | n/a | 12.1% |
| FY2014 | 4.0% | 4.2% | 13.1% |
| FY2013 | 5.1% | 5.6% | 14.2% |
| FY2012 | 4.0% | 4.6% | 16.4% |
| FY2011 | 1.4% | 2.9% | 16.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | n/a | |
| Q1 FY26 | n/a | n/a | n/a | |
| Q2 FY25 | n/a | n/a | n/a | |
| Q4 FY25 | −30.0% | −39.4 pts | −13.4% | |
| Q3 FY25 | −34.3% | −17.7 pts | −15.7% | |
| Q2 FY25 | −10.9% | +53.5 pts | −9.4% | |
| Q1 FY25 | 5.1% | +100.6 pts | −9.2% | |
| Q4 FY24 | 9.4% | +105.8 pts | −6.9% | |
| Q3 FY24 | −16.6% | n/a | −14.5% | |
| Q2 FY24 | −64.4% | +20.5 pts | −20.7% | |
| Q1 FY24 | −95.5% | n/a | −26.1% | |
| Q4 FY23 | −96.4% | n/a | −21.1% |
Against its peers
Companies in Drug Manufacturers - General nearest Lifecore Biomedical's size, closest first, today.
| Company | Profit margin |
|---|---|
| LFCRLifecore Biomedical | n/m |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| LFVNLifevantage | 2.8% |
| ABUSArbutus Biopharma | 84.2% |
| SPROSpero Therapeutics | 15.7% |
| Peer median | 13.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Lifecore Biomedical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.